FDA Approves ADHD Treatment Cotempla XR-ODT
The once-daily treatment is an oral formulation of central nervous system stimulant methylphenidate.
The US Food and Drug Administration (FDA) has approved Cotempla XR-ODT (methylphenidate) for the treatment of attention-deficit/hyperactivity disorder (ADHD).
Cotempla XR-ODT, by specialty pharmaceutical company Neos Therapeutics, is an orally disintegrating tablet (ODT) formulation of central nervous system stimulant methylphenidate. It was tested and intended for once-daily, extended-release ADHD treatment in children.
Methylphenidate has been prominent in treatment for attention-deficit disorder (ADD) and narcolepsy.
Neos originally submitted a New Drug Application (NDA) to the FDA for Cotempla XR-ODT in January 2015, following a successful Phase III clinical trial. The multicenter, randomized, double-blind, placebo-controlled laboratory classroom study compared treatment versus placebo in ADHD children patients aged 6-12 years old.
Versus placebo, the treatment met all primary and secondary efficacy endpoints and showed statistically significant improvements in the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Scale and Permanent Product Measure of Performance (PERMP) Scale.
However, the FDA Center for Drug Evaluation and Research submitted a Complete Response Letter to Neos in November 2015, requiring a bridging study to demonstrate bioequivalence between the clinical trial material and the potentially marketed drug. They also required an assessment of food effect, provided validation, and 3 months’ worth of stability data.
Neos submitted the requested information in the following month.
Related Coverage
Many Primary Care Patients with Depression Doing Poorly after Ten Years
Even Low Levels of Alcohol Exposure Can Change Shape of Babies' Faces
